Alteration of Liposomal-Surface Properties with Synthetic Glycolipids

  • M. M. Ponpipom
  • T. Y. Shen


Liposomes have been proposed as carriers to introduce biologically active agents into cells, and their various applications have been extensively investigated.1–3 The tissue distribution and clearance kinetics of drug-containing liposomes are known to be affected by phospholipid composition, size and surface charge.4,5 Small liposomes, were shown to be better than larger liposomes for specific delivery of their contents to target cells in-vivo.6 Although successes have been amply demonstrated for in-vitro targeting of liposomes including covalent attachment of proteins onto the surface of liposomes,7,8 no in-vivo specificity has yet been reported for any liposomes thus modified. The interaction of liposomes with cells in-vivo occurs in quite a complex biological milieu and the binding of proteins from this milieu may also have important effects on liposome behaviour.9 Our approach to improve liposomes as a drug-delivery system is to use small synthetic glycolipids as cell-surface ligands to alter the tissue distribution of the modified liposomes in various tissues and organs.


Mouse Peritoneal Macrophage Carbohydrate Determinant Plasma High Density Lipoprotein Liposomal Surface Control Liposome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. Gregoriadis, Use of monoclonal antibodies and liposomes to improve drug delivery, Drugs, 24:261 (1982)PubMedCrossRefGoogle Scholar
  2. 1a.
    G. Gregoriadis, The carrier potential of liposomes in biology and medicine, N. Engl. J. Med., 295:704, (1976).PubMedCrossRefGoogle Scholar
  3. 1b.
    G. Gregoriadis, The carrier potential of liposomes in biology and medicine, N. Engl. J. Med., 295:765 (1976).PubMedCrossRefGoogle Scholar
  4. 2.
    S.B. Kay, Liposomes — Problems and promise as selective drug carriers, Cancer Treatm. Rev. 8:27 (1981).CrossRefGoogle Scholar
  5. 3.
    B.E. Ryman and D.A. Tyrrell, Liposomes — Bags of potential, Essays Biochem. 16:49 (1980).PubMedGoogle Scholar
  6. 4.
    R.L. Juliano and D. Stamp, The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs, Biochem. Biophys. Res. Commun,, 63:651 (1975).PubMedCrossRefGoogle Scholar
  7. 5.
    Y.E. Rahman, E.A. Cerny, K.R. Patel, E.H. Lau, and B.J. Wright, Differential uptake of liposomes varying in size and lipid composition by parenchymal and Kupffer cells of mouse liver, Life Sci., 31:2061 (1982).PubMedCrossRefGoogle Scholar
  8. 6.
    P. Machy and L.D. Leserman, Small liposomes are better than large liposomes for specific drug delivery in-vitro, Biochim. Biophys. Acta, 730:313 (1983).PubMedCrossRefGoogle Scholar
  9. 7.
    L.D. Leserman, P. Machy, and J. Barbet, Cell-specific drug transfer from liposomes bearing monoclonal antibodies, Na ture, 293:226 (1981).Google Scholar
  10. 8.
    T.D. Heath, J.A. Montgomery, J.R. Piper, and D. Papahadjopoulos, Antibody-targeted liposomes: Increase in specific toxicity of methotrexate-r-aspartate, Proc. Natl. Acad. Sci. USA, 80:1377 (1983).PubMedCrossRefGoogle Scholar
  11. 9.
    R.L. Juliano and G. Lin, The interaction of plasma proteins with liposomes: Protein binding and effects on the clotting and complement systems, in “Liposomes and Immunobiology,” B.H. Tom and H.R. Six, eds., Elsevier/North Holland, New York (1980).Google Scholar
  12. 10.
    M.D. Saunders and T.E. Timell, The acid hydrolysis of glycosides, Carbohydr. Res., 6:121 (1968).CrossRefGoogle Scholar
  13. 11.
    S. Roseman, in “Cell Membranes, Biochemistry, Cell Biology and Pathology” G. Weissmann and R. Claiborne, eds., HP Publishing Co., New York (1975).Google Scholar
  14. 12.
    M.M. Ponpipom, R.L. Bugianesi, and T.Y. Shen, Cell surface carbohydrates for targeting studies, Can. J. Chem., 58:214 (1980).CrossRefGoogle Scholar
  15. 13.
    J.C. Chabala and T.Y. Shen, The preparation of 3-cholesteryl 6-(glycosylthio)hexyl ethers and their incorporation into liposomes, Carbohyd. Rec., 67:55 (1978).CrossRefGoogle Scholar
  16. 14.
    M.M. Ponpipom, R.L. Bugianesi, T.Y. Shen, and A. Friedman, Glycolipids as potential immunologic adjuvants, J. Med. Chem., 23:1184 (1980).PubMedCrossRefGoogle Scholar
  17. 15.
    G. Gregoriadis, C. Kirby, and J. Senior, Targeting of drugs with liposomes: Studies on optimization in “Optimization of Drug Delivery”, H. Bundgaard, A.B. Hansen, and H. Kofod, eds., Munksgaard, Copenhagen (1982).Google Scholar
  18. 16.
    R.A. Demel and B. De Kruyff, The function of sterols in membranes, Biochim. Biophys. Acta, 457:109 (1976).PubMedCrossRefGoogle Scholar
  19. 17.
    L. Damen, J. Regts, and G. Scherphof, Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins: Dependence on cholesterol content and phospholipid composition, Biochim. Biophys. Acta, 665:538 (1981).PubMedCrossRefGoogle Scholar
  20. 18.
    C. Kirby, J. Clarke, and G. Gregoriadis, Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum, FEBS Lett., 111:324 (1980).PubMedCrossRefGoogle Scholar
  21. 19.
    P.S. Wu, H.M. Wu, G.W. Tin, J.R. Schuh, W.R. Croasmun, J.D. Baldeschwieler, T.Y. Shen, and M.M. Ponpipom, Stability of carbohydrate-modified vesicles in-vivo: Comparative effects of ceramide and cholesterol glycoconjugates, Proc. Natl. Acad. Sci. USA, 79:5490 (1982).PubMedCrossRefGoogle Scholar
  22. 20.
    P.S. Wu, G.W. Tin, and J.D. Baldeschwieler, Phagocytosis of carbohydrate-modified phospolipid vesicles by macrophages, Proc. Natl. Acad. Sci. USA, 78:2033 (1981).PubMedCrossRefGoogle Scholar
  23. 21.
    G. Gregoriadis and A.C. Allison, eds., “Liposomes in Biological Systems”, Wiley, New York (1980).Google Scholar
  24. 22.
    G. Poste, Liposome targeting in-vivo: Problems and opportunities, Biol. Cell, 47:19 (1983).Google Scholar
  25. 23.
    F.C. Szoka, Jr. and E. Mayhew, Alteration of liposomal disposition in-vivo by bilayer situated carbohydrates, Biochem. Biophys. Res. Commun., 110:140 (1983).PubMedCrossRefGoogle Scholar
  26. 24.
    M.M. Ponpipom, M.S. Wu, J.C. Robbins, and T.Y. Shen, Synthesis of 6-(5-cholesten-3β-yloxy)hexyl 4–0-(6-deoxy-β-D-galactopyranosyl)-1-thio-β-Dglucopyranoside and derivatives thereof for in-vivo liposome studies, Carbohyd. Res., 118:47 (1983).CrossRefGoogle Scholar
  27. 25.
    M.S. Wu, J.C. Robbins, R.L. Bugianesi, M.M. Ponpipom, and T.Y. Shen, Modified in-vivo behaviour of liposomes containing synthetic glycolipids, Biochim. Biophys. Acta, 674:19 (1981).PubMedCrossRefGoogle Scholar
  28. 26.
    P.D. Stahl, J.S. Rodman, M.J. Miller, and P.H. Schlesinger, Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages, Proc. Natl. Acad. Sci. USA, 75:1399 (1978).PubMedCrossRefGoogle Scholar
  29. 27.
    M.R. Mauk, R.C. Gamble, and J.D. Baldeschwieler, Vesicle targeting: Timed release and specificity for leukocytes in mice by subcutaneous injection, Science, 207:309 (1980).PubMedCrossRefGoogle Scholar
  30. 28.
    M.R. Mauk, R.C. Gamble, and J.D. Baldeschwieler, Targeting of lipid vesicles: Specificity of carbohydrate receptor analogue for leukocytes in mice, Proc.Natl. Acad. Sci. USA, 77:4430 (1980).PubMedCrossRefGoogle Scholar
  31. 29.
    R.T. Proffitt, L.E. Williams, C.A. Presant, G.W. Tin, J.J. Uliano, R.C. Gamble, and J.D. Baldeschwieler, Tumor-imaging potential of liposomes loaded with 111In-NTA: Biodistribution in mice, J. Nucl. Med., 24:45 (1983).PubMedGoogle Scholar
  32. 30.
    R.T. Proffitt, L.E. Williams, C.A. Presant, G.W. Tin, J.A. Uliano, R.C. Gamble, and J.D. Baldeschwieler, Liposomal blockade of the reticuloendothelial system: Improved tumor-imaging with small unilamellar vesicles, Science, 220:502 (1983).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • M. M. Ponpipom
    • 1
  • T. Y. Shen
    • 1
  1. 1.Merck Sharp & Dohme Research LaboratoriesRahwayUSA

Personalised recommendations